Ria Francesco, Pirolli Davide, Di Sante Gabriele, Righino Benedetta, Gremese Elisa, Gervasoni Jacopo, Nicolò Chiara, Giardina Bruno, Ferraccioli Gianfranco, De Rosa Maria Cristina
Institute of General Pathology, Università Cattolica del Sacro Cuore, Rome, Italy.
Institute of General Pathology, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S., Rome, Italy.
ACS Med Chem Lett. 2019 Mar 13;10(4):644-649. doi: 10.1021/acsmedchemlett.8b00601. eCollection 2019 Apr 11.
Autoreactive T cells specific to human collagen type II have a crucial role in the development of rheumatoid arthritis (RA) in the context of MHC class II allele HLA-DRB1-*04. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen bound to the allele MHC of class II may thus represent the target for the development of new drugs against RA. In this study, a structure-based pharmacophore model for potential small molecule inhibitors was developed from protein-protein interface structure. The 3D model obtained was used for a virtual screening workflow, which resulted in three hits for experimental follow up. Three compounds have been identified that interfere with the TCR/collagenII-MHCII ( values below 10 μM) and open up new possibilities in the treatment of RA.
在MHC II类等位基因HLA - DRB1 - *04的背景下,对人II型胶原具有特异性的自身反应性T细胞在类风湿性关节炎(RA)的发展中起关键作用。因此,T细胞受体(TCR)与II类等位基因MHC结合的II型胶原之间的蛋白质 - 蛋白质相互作用可能代表了开发抗RA新药的靶点。在本研究中,基于蛋白质 - 蛋白质界面结构开发了一种用于潜在小分子抑制剂的基于结构的药效团模型。所获得的三维模型用于虚拟筛选流程,结果产生了三个用于实验后续研究的命中物。已鉴定出三种化合物可干扰TCR/胶原II - MHCII(IC50值低于10μM),为RA的治疗开辟了新的可能性。